Edition:
United States

Kindred Biosciences Inc (KIN.OQ)

KIN.OQ on NASDAQ Stock Exchange Capital Market

9.80USD
23 May 2018
Change (% chg)

$0.20 (+2.08%)
Prev Close
$9.60
Open
$9.80
Day's High
$9.85
Day's Low
$9.60
Volume
30,776
Avg. Vol
17,138
52-wk High
$10.15
52-wk Low
$6.60

Chart for

About

Kindred Biosciences, Inc. is a development-stage biopharmaceutical company. The Company is focused on developing therapies for pets. The Company's product pipeline consists of small molecules and biologics for a range of indications in dogs, cats and horses. The Company is developing product candidates for over 20 indications... (more)

Overall

Beta: 0.21
Market Cap(Mil.): $225.49
Shares Outstanding(Mil.): 27.84
Dividend: --
Yield (%): --

Financials

  KIN.OQ Industry Sector
P/E (TTM): -- 84.06 32.75
EPS (TTM): -1.17 -- --
ROI: -34.47 1.57 14.38
ROE: -34.50 2.43 16.07

BRIEF-Kindred Biosciences Reports Q1 Loss Per Share $0.36

* KINDRED BIOSCIENCES ANNOUNCES FIRST QUARTER 2018 FINANCIAL RESULTS

May 08 2018

FDA approves Kindred treatment for problem weight loss in cats

Kindred Biosciences Inc has received the first U.S. approval for a treatment for unintended weight loss in cats, opening the door to a market it says extends to up to 9 million potential cases in the United States alone.

May 07 2018

UPDATE 1-FDA approves Kindred treatment for problem weight loss in cats

May 7 Kindred Biosciences Inc has received the first U.S. approval for a treatment for unintended weight loss in cats, opening the door to a market it says extends to up to 9 million potential cases in the United States alone.

May 07 2018

FDA approves Kindred's weight-loss ointment for cats

May 7 Kindred Biosciences inc said on Monday the U.S. Food and Drug Administration had approved its topical treatment for unintended weight loss in cats.

May 07 2018

BRIEF-Kindred Biosciences Says Entered Into At Market Issuance Sales Agreement

* KINDRED BIOSCIENCES SAYS ENTERED INTO AT MARKET ISSUANCE SALES AGREEMENT - SEC FILING

May 07 2018

BRIEF-Kindred Biosciences Receives FDA Approval Of Mirataz For The Management Of Weight Loss In Cats

* KINDRED BIOSCIENCES RECEIVES FDA APPROVAL OF MIRATAZ™ (MIRTAZAPINE TRANSDERMAL OINTMENT) FOR THE MANAGEMENT OF WEIGHT LOSS IN CATS

May 07 2018

BRIEF-Kindred Biosciences Announces Board Appointments

* KINDRED BIOSCIENCES ANNOUNCES THE APPOINTMENT OF DR. ERNEST MARIO AND DR. JOSEPH MCCRACKEN TO ITS BOARD OF DIRECTORS Source text for Eikon: Further company coverage:

Apr 25 2018

BRIEF-Kindred Biosciences Q4 Loss Per Share $0.35

* KINDRED BIOSCIENCES ANNOUNCES FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS

Mar 01 2018

BRIEF-Kindred Biosciences Inc Files For Mixed Shelf Of Up To $150 Million

* KINDRED BIOSCIENCES INC FILES FOR MIXED SHELF OF UP TO $150 MILLION – SEC FILING‍​ Source text - (http://bit.ly/2risHPv) Further company coverage:

Jan 18 2018

BRIEF-KindredBio Announces Submission Of European Medicines Agency Filing For Mirataz

* KINDREDBIO ANNOUNCES SUBMISSION OF EUROPEAN MEDICINES AGENCY FILING FOR MIRATAZ™

Dec 21 2017

Earnings vs. Estimates